rs9263726 is a specific genetic marker for allopurinol-induced severe cutaneous adverse reactions in Chinese patients

被引：5
作者：
Chen, Zhiyao [1 ]
Zhang, Shichao [1 ,2 ]
Zhang, Jingjing [1 ]
Zhang, Yan [1 ]
Xue, Ling [1 ]
Miao, Liyan [1 ]
机构：
[1] Soochow Univ, Res Lab, Dept Clin Pharmacol, Affiliated Hosp 1, Suzhou 215006, Peoples R China
[2] Soochow Univ, Coll Pharmaceut Sci, Suzhou 215006, Peoples R China
来源：
PERSONALIZED MEDICINE | 2015年 / 12卷 / 06期
基金：
中国国家自然科学基金;
关键词：
allopurinol; Chinese patients; HLA-B*58:01; rs9263726; SCARs; TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; INFLAMMATORY-BOWEL-DISEASE; DRUG-REACTIONS; HAN CHINESE; HYPERURICEMIA; GOUT; FEBUXOSTAT; GUIDELINES; MANAGEMENT;
D O I：
10.2217/pme.15.38
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aim: Screening of an easily detectable biomarker to replace the HLA allele B variant (HLA-B*58:01) testing for predicting allopurinol-induced severe cutaneous adverse reactions (SCARs) in eastern Chinese patients. Methods: Six SNPs and the HLA-B*58:01 were analyzed in 17 patients with allopurinol-induced SCARs and in 151 control patients. SNPs were analyzed by pyrosequencing, and HLA-B*58:01 was evaluated by sequencing-based techniques. Consistency between sequencing-based HLA-B*58:01 testing and pyrosequencing-based rs9263726 testing was investigated in 262 individuals. Results: A significant association with allopurinol-induced SCARs was found at rs9263726 (odds ratio: 108.8) and HLA-B*58:01 (odds ratio: 108.8). The kappa values between sequencing-based HLA-B*58:01 testing and pyrosequencing-based rs9263726 testing were 0.96 (>0.75), demonstrating they were well coincident with each other. Conclusion: rs9263726 was a useful surrogate of HLA-B*58:01 testing for prescreening allopurinol-induced SCARs in eastern Chinese patients.
引用
收藏
页码：585 / 592
页数：8
相关论文
共 27 条
[1]   Pharmacogenetics of cutaneous adverse drug reactions [J].
Aihara, Michiko .
JOURNAL OF DERMATOLOGY, 2011, 38 (03) :246-254
[2]   CLINICAL CLASSIFICATION OF CASES OF TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME, AND ERYTHEMA MULTIFORME [J].
BASTUJIGARIN, S ;
RZANY, B ;
STERN, RS ;
SHEAR, NH ;
NALDI, L ;
ROUJEAU, JC .
ARCHIVES OF DERMATOLOGY, 1993, 129 (01) :92-96
[3]   Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout [J].
Bisht, Manisha ;
Bist, S. S. .
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 73 (06) :597-600
[4]   Febuxostat: A selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout [J].
Bruce, Susan P. .
ANNALS OF PHARMACOTHERAPY, 2006, 40 (12) :2187-2194
[5]   HLA-B☆58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study [J].
Cheng, L. ;
Xiong, Y. ;
Qin, C. Z. ;
Zhang, W. ;
Chen, X. P. ;
Li, J. . ;
Zhou, H. H. .
BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (02) :555-558
[6]   Association between HLA-B☆58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong [J].
Chiu, M. L. S. ;
Hu, M. ;
Ng, M. H. L. ;
Yeung, C. K. ;
Chan, J. C-Y. ;
Chang, M. M. ;
Cheng, S. H. ;
Li, L. ;
Tomlinson, B. .
BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (01) :44-49
[7]   Assessment and Management of Low Bone Density in Inflammatory Bowel Disease and Performance of Professional Society Guidelines [J].
Etzel, Jason P. ;
Larson, Meaghan F. ;
Anawalt, Bradley D. ;
Collins, Judith ;
Dominitz, Jason A. .
INFLAMMATORY BOWEL DISEASES, 2011, 17 (10) :2122-2129
[8]  
French LE, 2006, ALLERGOL INT, V55, P9
[9]   Hyperuricemia, gout and the kidney [J].
Gibson, Terence .
CURRENT OPINION IN RHEUMATOLOGY, 2012, 24 (02) :127-131
[10]   Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing [J].
Hershfield, M. S. ;
Callaghan, J. T. ;
Tassaneeyakul, W. ;
Mushiroda, T. ;
Thorn, C. F. ;
Klein, T. E. ;
Lee, M. T. M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (02) :153-158
123